Acer Therapeutics Inc. (NASDAQ: ACER) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts. On September 25, 2018 I published my first article on Acer in which I described the Company's history and its business plan to focus on orphan and ultra-orphan diseases with significant unmet need. I also described in some detail the background and market potential of Acer's first two late stage clinical drug candidates for the U.S. market for severe genetic disorders:
- EDSIVOâ„¢ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (“vEDS”). The Company anticipates,